Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 3, 1997, Pages 319-324

  Madsen, Hanne ^a   Rasmussen, Birgitte Buur ^a   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYDESIPRAMINE; 2 HYDROXYIMIPRAMINE; CAFFEINE; CYTOCHROME P450; DESIPRAMINE; DRUG METABOLITE; HYDROCORTISONE; IMIPRAMINE; MEPHENYTOIN; PROGUANIL; QUINIDINE; SPARTEINE;

ADULT; ARTICLE; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; IMIPRAMINE; MALE; METHYLATION; MIXED FUNCTION OXYGENASES; PHENOTYPE; REGRESSION ANALYSIS;

EID: 0030898353     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90164-8     Document Type: Article

References (40)

1. Gram LF. Imipramine: a model substance in pharmacokinetic research. Acta Psychiatr Scand Suppl 1988; 78:81-4.
2. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986;40: 543-9.
3. Brøsen K, Gram LF, Klysner R, Bech P. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986;30:43-9.
4. Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991;49:609-17.
5. Madsen H, Nielsen K, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol 1995;39:433-9.
6. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983;15:388-90.
7. Christensen J, Gram LF, Kofod B, Rafaelsen OJ. Imipramine metabolism in man. Psychopharmacologia 1967;11:255-64.
8. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
9. Skjelbo E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R ratio): a population study. Br J Clin Pharmacol 1993;35:331-4.
10. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4′-hy.droxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994;37:237-42.
11. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Guengerich FP, Beaune P, et al. The major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
12. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45: 1211-4.
13. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
14. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-6.
15. Perel JM, Shostak M, Gann E, Kantor SJ, Glassman AH. Pharmacodynamics of imipramine and clinical outcome in depressed patients. In: Gottshalk LA, Merlis S, editors. Pharmacokinetics of psychoactive drugs: blood levels and clinical response. New York: Spectrum, 1976:229-41.
16. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988;26:363-72.
17. Brøsen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985;57:357-60.
18. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-700.
19. Berthou F, Flinois J, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991;19:561-7.
20. Rasmussen BB, Brøsen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase and N-acetyl transferase activity in humans. Ther Drug Monit 1996; 18:254-62.
21. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-65.
22. Rasmussen BB, Brøsen K. Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;676:169-74.
23. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 1994;4:109-16.
24. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
25. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
26. Drøhse A, Bathum L, Brøsen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989;27: 620-5.
27. Sanz EJ, Villén T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotype in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45: 495-9.
28. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993;36:105-8.
29. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Brøsen K. Proguanil metabolism and efficacy in relation to S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996;59:304-11.
30. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
31. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73.
32. Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-95.
33. Lykkesfeldt J, Loft S, Poulsen HE. Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Appl 1994;660:23-9.
34. Nielsen F, Nielsen KK, Brøsen K. Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by highperformance liquid chromatography. J Chromatogr B Biomed Appl 1994;660:103-10.
35. Nielsen KK, Brøsen K. High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. J Chromatogr 1993;612:87-94.
36. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994;37:413-20.
37. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlation among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmocol Ther 1993;54:621-9.
38. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
39. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6β-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci 1995;84:292-4.
40. Kalow W, Bing-Kou T. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53:503-15.